

Statement Under Article 19(1)

Replacement sheets 24-28 are enclosed. Please substitute these replacement sheets in place of the sheets 24-28 of the application as filed. Pursuant to PCT Administrative Instruction § 205, the changes to the claims is noted beginning on the next page with the support in the specification as originally filed indicated therein.

Amendments to the Claims: Remarks

Claim 1 replaces original claim 1. Claim 1 as amended has deleted the language “a fragment of SEQ ID NO:1” and “a fragment of SEQ ID NO:2”, and has changed “a nucleic acid sequence fully complementary to SEQ ID NO:1 or a fragment thereof” and “a nucleic acid sequence fully complementary to SEQ ID NO:2 or a fragment thereof” to read “and complements of the preceding”.

Claim 2 replaces original claim 2. Claim 2 has been amended to be consistent with replacement claim 1.

Claim 3 is new. The original specification contained no claim 3. Support for new claim 3 is present on page 7 (Table 1), and on page 7, line 4 of published WO2005/047487.

Claim 4 replaces original claim 4. Claim 4 has been amended to be consistent with replacement claim 1.

Claim 5 replaces original claim 5. Claim 5 has been amended to be consistent with replacement claim 1.

Claim 6 replaces original claim 6. Claim 6 has been amended to be consistent with replacement claim 1.

Claims 7 and 8 are unchanged.

Claim 9 replaces original claim 9. Claim 9 has been amended to be dependent on claim 3 instead of claim 1.

Claims 10-23 (first occurrence) are unchanged.

Claim 24 replaces the second occurrence of claim 23. The second and repeat occurrence of claim 23 is now claim 24.

Claim 25 is new. Support for new claim 25 is present on page 5, line 31 to page 6, line 2, and page 7, lines 11-13 of WO2005/047487.


Claim 26 is new. Support for new claim 26 is present on page 5, line 31 to page 6, line 2, and page 7, lines 11-13 of WO2005/047487.

The Applicants respectfully contend that the remarks made by the Authorized Officer in the Written Opinion are inapplicable to the substitute claims.

Respectfully submitted,

GENERVON BIOPHARMACEUTICALS LLC

Date: April 7, 2006

By: 

James W. Collett, Ph.D., J.D.

Attorney for Applicant

Reg. No. 46,636

DUANE MORRIS LLP

101 West Broadway, Suite 900

San Diego, CA 92101-8285

Tel.: (619) 744-2240

Fax: (619) 744-2201

COPY